drugset / Trial / NCT02745184

Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis

NCT02745184 ↗

Phase 1/2 Completed 10 enrolled Shanghai East Hospital Regend Therapeutics · collab
NaSingle-groupOpen-labelTreatment

Summary

Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease characterized by a progressive damage of lung structure and decline in lung function.This study intends to carry out an open, single-center, non-randomized, self control phase I clinical trial. During the treatment, lung stem cells will be isolated from patients' own bronchi and expanded in vitro. Cultured cells will be injected directly into the lesion by fiberoptic bronchoscopy after lavage. After 24-week observation, the investigators will evaluate the safety and efficacy of the treatment by measuring the key clinical indicators.

Timeline

Start
2017-03-30
Primary completion
2020-08-31
Completion
2020-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lung stem cells Unknown 500000 cells/kg Other
Subject Lung stem cells Unknown 5e+06 cells/kg Other